medigraphic.com
ISSN 2683-1678 (Impreso)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2018, Número 3

<< Anterior Siguiente >>

Rev Latin Infect Pediatr 2018; 31 (3)


Epidemiología y tratamiento de la tuberculosis por Mycobacterium bovis en niños

Mascareñas-de los Santos AH, González-Saldaña N, Castillo-Bejarano JI

Idioma: Español
Referencias bibliográficas: 32
Paginas: 97-100
Archivo PDF: 157.08 Kb.


RESUMEN

La tuberculosis (TB) zoonótica es un problema de salud pública mundial con escasos reportes. Durante 2016 se presentaron 147,000 casos nuevos de TB por M. bovis. A nivel mundial la prevalencia promedio es de 1%, superior al 0.3% descrito en la región de las Américas. La resistencia intrínseca a pirazinamida y la ausencia de ensayos clínicos aleatorizados son factores para los cuales no se ha determinado el tratamiento más adecuado.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. de la Rua-Domenech R. Human Mycobacterium bovis infection in the United Kingdom: incidence, risks, control measures and review of the zoonotic aspects of bovine tuberculosis. Tuberculosis (Edinb). 2006; 86 (2): 77-109.

  2. Wigle WD, Ashley MJ, Killough EM, Cosens M. Bovine tuberculosis in humans in Ontario. The epidemiologic features of 31 active cases occurring between 1964 and 1970. Am Rev Respir Dis. 1972; 106 (4): 528-534.

  3. LoBue PA, Moser KS. Treatment of Mycobacterium bovis infected tuberculosis patients: San Diego County, California, United States, 1994-2003. Int J Tuber Lung Dis. 2004; 9 (3): 333-338.

  4. Dean GS, Rhodes SG, Coad M, Whelan AO, Cockle PJ, Clifford DJ et al. Minimum infective dose of Mycobacterium bovis in cattle. Infect Immun. 2005; 73 (10): 6467-6471.

  5. O’Reilly LM, Daborn CJ. The epidemiology of Mycobacterium bovis infections in animals and man: a review. Tubercle Lung Dis. 1995; 76 (Suppl 1): 1-46.

  6. Grange JM, Yates MD. Zoonotic aspects of Mycobacterium bovis infection. Vet Microbiol. 1994; 40 (1-2): 137-151.

  7. Starke JR, Donald PR. Handbook of child & adolescent tuberculosis. Oxford University Press, New York, NY, 2016, p. 448.

  8. Müller B, Dürr S, Alonso S, Hattendorf J, Laisse CJ, Parsons SD et al. Zoonotic Mycobacterium bovis-induced tuberculosis in humans. Emerg Infect Dis. 2013; 19 (6): 899-908.

  9. Global tuberculosis report 2017. Geneva: World Health Organization; 2017.

  10. de Kantor IN, Ambroggi M, Poggi S, Morcillo N, Da Silva Telles MA, Osório Ribeiro M et al. Human Mycobacterium bovis infection in ten Latin American countries. Tuberculosis (Edinb). 2008; 88 (4): 358-365.

  11. Cordova E, Gonzalo X, Boschi A, Lossa M, Robles M, Poggi S, Ambroggi M. Human Mycobacterium bovis infection in Buenos Aires: epidemiology, microbiology and clinical presentation. Int J Tuber Lung Dis. 2012; 16 (3): 415-417.

  12. Pérez-Guerrero L, Milián-Suazo F, Arriaga-Díaz C, Romero-Torres C, Escartín-Chávez M. Epidemiología molecular de la tuberculosis bovina y humana en una zona endémica de Querétaro, México. Salud Pública de México. 2008; 50 (4): 286-291.

  13. Portillo-Gómez L, Sosa-Iglesias EG. Molecular identification of Mycobacterium bovis and the importance of zoonotic tuberculosis in Mexican patients. Int J Tuberc Lung Dis. 2011; 15 (10): 1409-1414.

  14. Cicero R, Olivera H, Hernández-Solis A, Ramírez-Casanova E, Escobar-Gutiérrez A. Frequency of Mycobacterium bovis as an etiologic agent in extrapulmonary tuberculosis in HIV-positive and -negative Mexican patients. Eur J Clin Microbiol Infect Dis. 2009; 28: 455-460.

  15. Laniado-Laborín R, Muñiz-Salazar R, García-Ortiz RA, Vargas-Ojeda AC, Villa-Rosas C, Oceguera-Palao L. Molecular characterization of Mycobacterium bovis isolates from patients with tuberculosis in Baja California, Mexico. Infect Genet Evol. 2014; 27: 1-5.

  16. Torres-Gonzalez P, Cervera-Hernandez M, Martinez-Gamboa A, Garcia-Garcia L, Cruz-Hervert LP, Bobadilla-del Valle M et al. Human tuberculosis. Caused by Mycobacterium bovis: a retrospective comparision with Mycobacterium tuberculosis in a Mexican tertiary care centre, 2000-2015. BMC Infectious Diseases. 2016; 16: 1-9.

  17. Rodwell TC, Moore M, Moser KS, Brodine SK, Strathdee SA. Tuberculosis from Mycobacterium bovis in binational communities, United States. Emerg Infect Dis. 2008; 14 (6): 909-916.

  18. Hlavsa MC, Moonan PK, Cowan LS, Navin TR, Kammerer JS, Morlock GP, Crawford JT, Lobue PA. Human Tuberculosis due to Mycobacterium bovis in the United States, 1995-2005. Clin Infect Dis. 2008; 47 (2): 168-175.

  19. Scott C, Cavanaugh JS, Pratt R, Silk BJ, LoBue P, Moonan PK. Human tuberculosis caused by Mycobacterium bovis in the United States, 2006-2013. Clin Infect Dis. 2016; 63 (5): 594-601.

  20. Centers for Disease Control and Prevention (CDC). Reported Tuberculosis in the United States, 2015. Atlanta, GA: US Department of Health and Human Services, CDC; 2016.

  21. Danker WM, Davis CE. Mycobacterium bovis as a significant cause of tuberculosis in children residing along the United States-Mexico border in the Baja California Region. Pediatrics. 2000; 105 (6): E79.

  22. Keating LA, Wheeler PR, Mansoor H, Inwald JK, Dale J, Hewinson RG et al. The pyruvate requirement of some members of the Mycobacterium tuberculosis complex is due to an inactive pyruvate kinase: implications for in vivo growth. Mol Microbiol. 2005; 56 (1): 163-174.

  23. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003; 167 (4): 603-662.

  24. Allix-Béguec C. Importance of identifying Mycobacterium bovis. Eur Respir J. 2010; 35 (3): 692-694.

  25. Pan-American Health Organization/World Health Organization. Manual para el diagnóstico bacteriológico de la tuberculosis. Normas y Guía Técnica. Parte II: Cultivo, 2008. Washington DC, USA: PAHO; 2008.

  26. LoBue PA, Moser KS. Treatment of Mycobacterium bovis infected tuberculosis patients: San Diego County, California, United States, 1994-2003. Int J Tuberc Lung Dis. 2005; 9 (3): 333-338.

  27. American Academy of Pediatrics. Tuberculosis In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018, pp. 829-853.

  28. Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd. Geneva. World Health Organization; 2014.

  29. Lan Z, Bastos M, Menzies D. Treatment of human disease due to Mycobacterium bovis: a systematic review. Eur Respir J. 2016; 48 (5): 1500-1503.

  30. Grayson L. The use of antibiotics, a clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs. 6th ed. ASM press. 2017.

  31. Vazquez-Chacon CA, Martínez-Guarneros A, Couvin D, González-Y-Merchand JA, Rivera-Gutierrez S, Escobar-Gutierrez A et al. Human multidrug-resistant Mycobacterium bovis infection in Mexico. Tuberculosis (Edinb). 2015; 95 (6): 802-809. doi: 10.1016/j.tube.2015.07.010.

  32. Hughes VM, Skuce R, Doig C, Stevenson K, Sharp JM, Watt B. Analysis of multidrug-resistant Mycobacterium bovis from three clinical samples from Scotland. Int J Tuberc Lung Dis. 2003; 7 (12): 1191-1198.




2020     |     www.medigraphic.com